Cell Therapy Next Current Issue
The following articles appeared in the print edition of Cell Therapy Next.
Table of Contents
- Cell therapy amid COVID-19: New anxieties and lessons learned Drew Amorosi
-
- Novel CAR-T uses scorpion toxin to target brain tumors Drew Amorosi
- C7R-GD2.CAR T Cells for patients with GD2-expressing brain tumors (GAIL-B) Drew Amorosi
- Genetically modified T cells in treating patients with recurrent or refractory malignant glioma Drew Amorosi
- Intracerebral EGFR-vIII CAR T Cells for recurrent glioblastoma Drew Amorosi
- Multi-antigen T-Cell Infusion Against Neuro-oncologic Disease Drew Amorosi
- Novel gamma-delta T-Cell therapy for treatment of patients with newly diagnosed glioblastoma Drew Amorosi
- Tisagenlecleucel in primary CNS lymphoma
- FDA clears IND application for CAR-T to treat ALL
-
- IND application cleared for cell therapy to treat COVID-19-related lung damage
- FDA clears IND application for natural killer cell-based COVID-19 therapy
- FDA grants anti-BCMA CAR-T orphan drug designation for advanced multiple myeloma
- Multi-antigen T-cell therapy gets orphan drug designation for AML
- Kymriah receives RMAT designation for follicular lymphoma
- Improving CAR T-Cell efficacy with combinatorial strategies Drew Amorosi
- Point-of-care manufacturing delivers effective CAR T cells faster Drew Amorosi
- CAR-T plus atezolizumab safe, effective in refractory diffuse large B-cell lymphoma Drew Amorosi
-
- Novel CD19/CD22 bispecific CAR-T effective, safe for advanced pediatric ALL Drew Amorosi
- Off-the-shelf CAR T-cell therapy induces durable remissions in relapsed, refractory B-cell malignancies
- AlloVir, Baylor collaborate to develop COVID-19 T-cell therapy Eamon N. Dreisbach
- Novartis, TScan Therapeutics partner on cell therapies for solid tumors Drew Amorosi
- Researchers to collaborate on natural killer cell-based COVID-19 treatment